Published in Colloids Surf B Biointerfaces on October 20, 2011
Theranostic nanoparticles based on PEGylated hyaluronic acid for the diagnosis, therapy and monitoring of colon cancer. Biomaterials (2012) 1.10
Targeting hyaluronic acid family for cancer chemoprevention and therapy. Adv Cancer Res (2014) 0.96
Prostate cancer relevant antigens and enzymes for targeted drug delivery. J Control Release (2014) 0.93
A facile, one-step nanocarbon functionalization for biomedical applications. Nano Lett (2012) 0.92
Versatile RNA interference nanoplatform for systemic delivery of RNAs. ACS Nano (2014) 0.91
Biodegradable nanoparticles sequentially decorated with Polyethyleneimine and Hyaluronan for the targeted delivery of docetaxel to airway cancer cells. J Nanobiotechnology (2015) 0.91
A nanoparticle formula for delivering siRNA or miRNAs to tumor cells in cell culture and in vivo. Nat Protoc (2014) 0.81
Nanoparticle delivery and combination therapy of gambogic acid and all-trans retinoic acid. Int J Nanomedicine (2014) 0.81
Induction of Cancer Cell Death by Hyaluronic Acid-Mediated Uptake of Cytochrome C. J Nanomed Nanotechnol (2015) 0.77
Hyaluronic acid-conjugated liposome nanoparticles for targeted delivery to CD44 overexpressing glioblastoma cells. Oncotarget (2016) 0.77
Delivery of tumor-homing TRAIL sensitizer with long-acting TRAIL as a therapy for TRAIL-resistant tumors. J Control Release (2015) 0.77
Paclitaxel-incorporated nanoparticles using block copolymers composed of poly(ethylene glycol)/poly(3-hydroxyoctanoate). Nanoscale Res Lett (2014) 0.77
Multiwalled Carbon Nanotube Functionalization with High Molecular Weight Hyaluronan Significantly Reduces Pulmonary Injury. ACS Nano (2016) 0.77
Utilization of Glycosaminoglycans/Proteoglycans as Carriers for Targeted Therapy Delivery. Int J Cell Biol (2015) 0.76
Characterization of Cell-Type-Specific Drug Transport and Resistance of Breast Cancers Using Tumor-Microenvironment-on-Chip. Mol Pharm (2016) 0.76
Theranostic nanoparticles for enzyme-activatable fluorescence imaging and photodynamic/chemo dual therapy of triple-negative breast cancer. Quant Imaging Med Surg (2015) 0.75
Optical clearing of skin enhanced with hyaluronic acid for increased contrast of optoacoustic imaging. J Biomed Opt (2016) 0.75
Double-layered hyaluronic acid/stearic acid-modified polyethyleneimine nanoparticles encapsulating (-)-gossypol: a nanocarrier for chiral anticancer drugs. J Mater Chem B Mater Biol Med (2014) 0.75
Improvement and enhancement of antibladder carcinoma cell effects of heteronemin by the nanosized hyaluronan aggregation. Int J Nanomedicine (2016) 0.75
Characterization of the Tumor Microenvironment and Tumor-Stroma Interaction by Non-invasive Preclinical Imaging. Front Oncol (2017) 0.75
Effect of Carboxymethylation on the Rheological Properties of Hyaluronan. PLoS One (2016) 0.75
Recent advances in hyaluronic acid-decorated nanocarriers for targeted cancer therapy. Drug Discov Today (2016) 0.75
Decoration of pH-sensitive copolymer micelles with tumor-specific peptide for enhanced cellular uptake of doxorubicin. Int J Nanomedicine (2016) 0.75
Overviews on the cellular uptake mechanism of polysaccharide colloidal nanoparticles. J Cell Mol Med (2017) 0.75
Tumor microenvironment dual-responsive core-shell nanoparticles with hyaluronic acid-shield for efficient co-delivery of doxorubicin and plasmid DNA. Int J Nanomedicine (2017) 0.75
Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol (2007) 17.80
Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer (2005) 13.49
CD44 is the principal cell surface receptor for hyaluronate. Cell (1990) 11.01
Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov (2005) 10.97
Drug delivery systems: entering the mainstream. Science (2004) 9.27
The dawning era of polymer therapeutics. Nat Rev Drug Discov (2003) 7.86
A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell (1991) 7.29
LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J Cell Biol (1999) 7.27
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A (2006) 6.90
The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul (2001) 6.59
Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer (2004) 6.47
Drug delivery and targeting. Nature (1998) 6.16
Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res (2004) 4.56
Hyaluronan: its nature, distribution, functions and turnover. J Intern Med (1997) 4.55
Multifunctional nanocarriers. Adv Drug Deliv Rev (2006) 4.46
The specific interaction of hyaluronic acid with cartillage proteoglycans. Biochim Biophys Acta (1972) 4.44
A lymphocyte molecule implicated in lymph node homing is a member of the cartilage link protein family. Cell (1989) 4.39
Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins. Lancet (1994) 3.69
A human lymphocyte homing receptor, the hermes antigen, is related to cartilage proteoglycan core and link proteins. Cell (1989) 3.57
Angiogenesis induced by degradation products of hyaluronic acid. Science (1985) 3.37
Mouse LYVE-1 is an endocytic receptor for hyaluronan in lymphatic endothelium. J Biol Chem (2001) 3.35
The hematopoietic and epithelial forms of CD44 are distinct polypeptides with different adhesion potentials for hyaluronate-bearing cells. EMBO J (1991) 3.20
Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol Rev (2002) 3.13
CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet (1995) 3.07
CD44 cell adhesion molecules. Mol Pathol (1999) 2.89
Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev (2008) 2.87
CD44 in cancer. Crit Rev Clin Lab Sci (2002) 2.83
Hyaluronan synthases. J Biol Chem (1997) 2.76
Nanomedicine: developing smarter therapeutic and diagnostic modalities. Adv Drug Deliv Rev (2006) 2.69
Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J Biol Chem (1994) 2.66
Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv Drug Deliv Rev (2002) 2.56
Hyaluronidases: their genomics, structures, and mechanisms of action. Chem Rev (2006) 2.47
Lecticans: organizers of the brain extracellular matrix. Cell Mol Life Sci (2000) 2.45
Molecular cloning of a novel hyaluronan receptor that mediates tumor cell motility. J Cell Biol (1992) 2.45
Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res (1993) 2.39
Synergistically integrated nanoparticles as multimodal probes for nanobiotechnology. Acc Chem Res (2008) 2.37
Distinct effects of two CD44 isoforms on tumor growth in vivo. J Exp Med (1991) 2.23
CD44 interaction with Na+-H+ exchanger (NHE1) creates acidic microenvironments leading to hyaluronidase-2 and cathepsin B activation and breast tumor cell invasion. J Biol Chem (2004) 2.20
Hyaluronan-binding proteins: tying up the giant. J Biol Chem (2001) 2.20
Induction of apoptosis of metastatic mammary carcinoma cells in vivo by disruption of tumor cell surface CD44 function. J Exp Med (1997) 2.11
Hyaluronan and homeostasis: a balancing act. J Biol Chem (2001) 2.03
Prevention of tumor metastasis formation by anti-variant CD44. J Exp Med (1993) 2.03
Hyaluronate and invasiveness of the rabbit V2 carcinoma. Proc Natl Acad Sci U S A (1979) 1.96
Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival. Am J Pathol (2000) 1.93
Overproduction of hyaluronan by expression of the hyaluronan synthase Has2 enhances anchorage-independent growth and tumorigenicity. Cancer Res (1999) 1.92
HA receptors: regulators of signalling to the cytoskeleton. J Cell Biochem (1996) 1.87
Solution structure of the link module: a hyaluronan-binding domain involved in extracellular matrix stability and cell migration. Cell (1996) 1.85
Expression of tumor markers hyaluronic acid and hyaluronidase (HYAL1) in head and neck tumors. Int J Cancer (2003) 1.82
Hyaluronan oligosaccharides inhibit anchorage-independent growth of tumor cells by suppressing the phosphoinositide 3-kinase/Akt cell survival pathway. J Biol Chem (2002) 1.81
Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody. J Control Release (2004) 1.80
HYAL1 hyaluronidase in prostate cancer: a tumor promoter and suppressor. Cancer Res (2005) 1.77
De-novo expression of CD44 and survival in gastric cancer. Lancet (1993) 1.75
CD44-dependent intracellular and extracellular catabolism of hyaluronic acid by hyaluronidase-1 and -2. J Biol Chem (2006) 1.69
The over-expression of HAS2, Hyal-2 and CD44 is implicated in the invasiveness of breast cancer. Exp Cell Res (2005) 1.62
Tumor cell-associated hyaluronan as an unfavorable prognostic factor in colorectal cancer. Cancer Res (1998) 1.59
Lectin-mediated drug targeting: history and applications. Adv Drug Deliv Rev (2004) 1.59
Stromal and epithelial expression of tumor markers hyaluronic acid and HYAL1 hyaluronidase in prostate cancer. J Biol Chem (2001) 1.58
Tumor targeting using anti-her2 immunoliposomes. J Control Release (2001) 1.56
Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. Mol Pharm (2005) 1.55
Interactions between human tumor cells and fibroblasts stimulate hyaluronate synthesis. Proc Natl Acad Sci U S A (1984) 1.50
Targeting of drugs. Nature (1977) 1.49
Expression of hyaluronidase by tumor cells induces angiogenesis in vivo. Proc Natl Acad Sci U S A (1996) 1.49
Expression of HYAL2 mRNA, hyaluronan and hyaluronidase in B-cell non-Hodgkin lymphoma: relationship with tumor aggressiveness. Int J Cancer (2005) 1.48
Identification of the hyaluronan receptor for endocytosis (HARE). J Biol Chem (2000) 1.45
Self-assembled hyaluronic acid nanoparticles for active tumor targeting. Biomaterials (2009) 1.43
In vivo inhibition of CD44 limits intra-abdominal spread of a human ovarian cancer xenograft in nude mice: a novel role for CD44 in the process of peritoneal implantation. Cancer Res (1997) 1.42
Tumor-homing multifunctional nanoparticles for cancer theragnosis: Simultaneous diagnosis, drug delivery, and therapeutic monitoring. J Control Release (2010) 1.37
TSG-6: an IL-1/TNF-inducible protein with anti-inflammatory activity. Cytokine Growth Factor Rev (1997) 1.37
The hyaluronan receptor RHAMM regulates extracellular-regulated kinase. J Biol Chem (1998) 1.36
Inhibition of prostate tumor cell hyaluronan synthesis impairs subcutaneous growth and vascularization in immunocompromised mice. Am J Pathol (2002) 1.36
HYAL1 hyaluronidase: a molecular determinant of bladder tumor growth and invasion. Cancer Res (2005) 1.36
Inhibition of tumor growth in vivo by hyaluronan oligomers. Int J Cancer (1998) 1.35
Differences in hyaluronic acid-mediated functions and signaling in arterial, microvessel, and vein-derived human endothelial cells. J Biol Chem (2000) 1.34
Protein expression of CD44 (standard and variant isoforms) in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, p53 expression, and patient survival. J Hepatol (2000) 1.33
Synthesis and selective cytotoxicity of a hyaluronic acid-antitumor bioconjugate. Bioconjug Chem (1999) 1.33
Selective expression and functional characteristics of three mammalian hyaluronan synthases in oncogenic malignant transformation. J Biol Chem (2004) 1.33
Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice. J Control Release (2007) 1.29
Hyaluronic acid-paclitaxel: antitumor efficacy against CD44(+) human ovarian carcinoma xenografts. Neoplasia (2007) 1.29
Hyaluronidases in cancer biology. Semin Cancer Biol (2008) 1.28
Internalization of hyaluronan by chondrocytes occurs via receptor-mediated endocytosis. J Cell Sci (1993) 1.27
Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells. Cancer Res (2001) 1.26
Loading mitomycin C inside long circulating hyaluronan targeted nano-liposomes increases its antitumor activity in three mice tumor models. Int J Cancer (2004) 1.26
A cell surface integral membrane glycoprotein of 85,000 mol wt (gp85) associated with triton X-100-insoluble cell skeleton. J Cell Biol (1984) 1.26
Hyaluronan synthase 3 overexpression promotes the growth of TSU prostate cancer cells. Cancer Res (2001) 1.25
Lymph node (but not spleen) invasion by murine lymphoma is both CD44- and hyaluronate-dependent. J Immunol (1995) 1.25
The hyaluronate receptor is identical to a glycoprotein of Mr 85,000 (gp85) as shown by a monoclonal antibody that interferes with binding activity. J Biol Chem (1987) 1.24
Urinary hyaluronic acid and hyaluronidase: markers for bladder cancer detection and evaluation of grade. J Urol (2000) 1.22
Hyaluronan (hyaluronic acid) and hyaluronectin in the extracellular matrix of human breast carcinomas: comparison between invasive and non-invasive areas. Int J Cancer (1992) 1.22
Hyperproduction of hyaluronan in neu-induced mammary tumor accelerates angiogenesis through stromal cell recruitment: possible involvement of versican/PG-M. Am J Pathol (2007) 1.22
CD44 variant isoforms in non-Hodgkin's lymphoma: a new independent prognostic factor. Blood (1995) 1.21
Hyaluronan expression in gastric cancer cells is associated with local and nodal spread and reduced survival rate. Br J Cancer (1999) 1.21
Target-specific intracellular delivery of siRNA using degradable hyaluronic acid nanogels. J Control Release (2007) 1.20
Degradation of newly synthesized high molecular mass hyaluronan in the epidermal and dermal compartments of human skin in organ culture. J Invest Dermatol (1991) 1.19
The intracellular drug delivery and anti tumor activity of doxorubicin loaded poly(gamma-benzyl L-glutamate)-b-hyaluronan polymersomes. Biomaterials (2010) 1.19
Drug targeting to the colon with lectins and neoglycoconjugates. Adv Drug Deliv Rev (2004) 1.18
Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer Res (2002) 1.18
Determination and modeling of kinetics of cancer cell killing by doxorubicin and doxorubicin encapsulated in targeted liposomes. Cancer Res (2004) 1.17
Isolation and characterization of human melanoma cell variants expressing high and low levels of CD44. Cancer Res (1991) 1.16
Targeted drug delivery to tumors: myths, reality and possibility. J Control Release (2011) 2.69
Celiac axis and common hepatic artery variations in 5002 patients: systematic analysis with spiral CT and DSA. Radiology (2010) 2.32
Release of hydrophobic molecules from polymer micelles into cell membranes revealed by Forster resonance energy transfer imaging. Proc Natl Acad Sci U S A (2008) 2.16
Orally fast disintegrating tablets: developments, technologies, taste-masking and clinical studies. Crit Rev Ther Drug Carrier Syst (2004) 2.06
Polycation gene delivery systems: escape from endosomes to cytosol. J Pharm Pharmacol (2003) 1.92
Fast release of lipophilic agents from circulating PEG-PDLLA micelles revealed by in vivo forster resonance energy transfer imaging. Langmuir (2008) 1.88
Cellular uptake mechanism and intracellular fate of hydrophobically modified glycol chitosan nanoparticles. J Control Release (2009) 1.81
Human extracellular matrix (ECM) powders for injectable cell delivery and adipose tissue engineering. J Control Release (2009) 1.70
Control of encapsulation efficiency and initial burst in polymeric microparticle systems. Arch Pharm Res (2004) 1.66
The effect and safety of the antithrombotic therapies in patients with atrial fibrillation and CHADS score 1. J Cardiovasc Electrophysiol (2009) 1.63
Three-Dimensional CT venography of varicose veins of the lower extremity: image quality and comparison with doppler sonography. AJR Am J Roentgenol (2008) 1.62
Collateral pathways in patients with celiac axis stenosis: angiographic-spiral CT correlation. Radiographics (2002) 1.53
Hydrotropic polymer micelle system for delivery of paclitaxel. J Control Release (2005) 1.52
Overcoming the barriers in micellar drug delivery: loading efficiency, in vivo stability, and micelle-cell interaction. Expert Opin Drug Deliv (2010) 1.51
Clinical and serological predictors for the recurrence of atrial fibrillation after electrical cardioversion. Europace (2009) 1.50
Analysis on the current status of targeted drug delivery to tumors. J Control Release (2012) 1.48
Recognizing extrahepatic collateral vessels that supply hepatocellular carcinoma to avoid complications of transcatheter arterial chemoembolization. Radiographics (2005) 1.48
Clinical predictors of recurrent venous thromboembolism: a single institute experience in Korea. Thromb Res (2008) 1.48
Defibillator electrogram T wave alternans as a predictor of spontaneous ventricular tachyarrhythmias in defibrillator recipients. Circ J (2008) 1.47
Targeted delivery of low molecular drugs using chitosan and its derivatives. Adv Drug Deliv Rev (2009) 1.46
Self-assembled hyaluronic acid nanoparticles for active tumor targeting. Biomaterials (2009) 1.43
Triple antithrombotic therapy versus dual antiplatelet therapy in patients with atrial fibrillation undergoing drug-eluting stent implantation. Coron Artery Dis (2015) 1.40
Balloon-occluded retrograde transvenous obliteration for gastric variceal bleeding: its feasibility compared with transjugular intrahepatic portosystemic shunt. Korean J Radiol (2003) 1.38
Tumor-homing multifunctional nanoparticles for cancer theragnosis: Simultaneous diagnosis, drug delivery, and therapeutic monitoring. J Control Release (2010) 1.37
Mechanisms of controlled drug release from drug-eluting stents. Adv Drug Deliv Rev (2006) 1.36
Molecular imprinting within hydrogels. Adv Drug Deliv Rev (2002) 1.36
Transcatheter arterial embolization of nonvariceal upper gastrointestinal bleeding with N-butyl cyanoacrylate. Korean J Radiol (2007) 1.35
Frosta: a new technology for making fast-melting tablets. Expert Opin Drug Deliv (2005) 1.33
Hydrotropic agents for study of in vitro paclitaxel release from polymeric micelles. J Control Release (2004) 1.31
Disulfide-cross-linked PEG-poly(amino acid)s copolymer micelles for glutathione-mediated intracellular drug delivery. Chem Commun (Camb) (2008) 1.31
Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice. J Control Release (2007) 1.29
Polymeric micelles and alternative nanonized delivery vehicles for poorly soluble drugs. Int J Pharm (2012) 1.25
Porous chitosan scaffold containing microspheres loaded with transforming growth factor-beta1: implications for cartilage tissue engineering. J Control Release (2003) 1.22
CT angiography for living kidney donors: accuracy, cause of misinterpretation and prevalence of variation. Korean J Radiol (2008) 1.22
Issues in long-term protein delivery using biodegradable microparticles. J Control Release (2010) 1.21
Diagnostic value of computed tomographic findings of nutcracker syndrome: correlation with renal venography and renocaval pressure gradients. Eur J Radiol (2010) 1.21
Superporous IPN hydrogels having enhanced mechanical properties. AAPS PharmSciTech (2003) 1.19
Hydrotropic polymeric micelles for enhanced paclitaxel solubility: in vitro and in vivo characterization. Biomacromolecules (2007) 1.18
Effect of polymer molecular weight on the tumor targeting characteristics of self-assembled glycol chitosan nanoparticles. J Control Release (2007) 1.18
Biodegradable polymers for microencapsulation of drugs. Molecules (2005) 1.18
Smart nanocarrier based on PEGylated hyaluronic acid for cancer therapy. ACS Nano (2011) 1.18
Engineered polymers for advanced drug delivery. Eur J Pharm Biopharm (2008) 1.17
Nonhepatic arteries originating from the hepatic arteries: angiographic analysis in 250 patients. J Vasc Interv Radiol (2006) 1.16
Role of computed tomographic angiography in the detection and comprehensive evaluation of persistent sciatic artery. J Vasc Surg (2005) 1.14
Hepatic arterial and portal venous phase helical CT in patients treated with transcatheter arterial chemoembolization for hepatocellular carcinoma: added value of unenhanced images. Radiology (2002) 1.14
Transcatheter arterial embolization of arterial esophageal bleeding with the use of N-butyl cyanoacrylate. Korean J Radiol (2009) 1.14
Acute iliofemoral deep vein thrombosis: evaluation of underlying anatomic abnormalities by spiral CT venography. J Vasc Interv Radiol (2004) 1.14
Elastic, superporous hydrogel hybrids of polyacrylamide and sodium alginate. Macromol Biosci (2006) 1.14
Accelerated chondrocyte functions on NaOH-treated PLGA scaffolds. Biomaterials (2005) 1.12
Spontaneous dissection of the splanchnic arteries: CT findings, treatment, and outcome. AJR Am J Roentgenol (2013) 1.12
Hydrotropic solubilization of paclitaxel: analysis of chemical structures for hydrotropic property. Pharm Res (2003) 1.12
Transcatheter arterial chemoembolization for hepatocellular carcinomas in patients with celiac axis occlusion. J Vasc Interv Radiol (2002) 1.12
Self-assembled glycol chitosan nanoparticles for the sustained and prolonged delivery of antiangiogenic small peptide drugs in cancer therapy. Biomaterials (2008) 1.12
Effective repair of traumatically injured spinal cord by nanoscale block copolymer micelles. Nat Nanotechnol (2009) 1.12
Magnetic resonance imaging findings of isolated right ventricular hypoplasia. Int J Cardiovasc Imaging (2012) 1.11
Smart Polymeric Gels: Redefining the Limits of Biomedical Devices. Prog Polym Sci (2007) 1.11
Recent developments in superporous hydrogels. J Pharm Pharmacol (2007) 1.11
Ultrasound and fluoroscopy-guided placement of central venous ports via internal jugular vein: retrospective analysis of 1254 port implantations at a single center. Korean J Radiol (2012) 1.11
Theranostic nanoparticles based on PEGylated hyaluronic acid for the diagnosis, therapy and monitoring of colon cancer. Biomaterials (2012) 1.10
Image quality of adaptive iterative dose reduction 3D of coronary CT angiography of 640-slice CT: comparison with filtered back-projection. Int J Cardiovasc Imaging (2012) 1.09
Advances in superporous hydrogels. J Control Release (2005) 1.07
Transcatheter arterial chemoembolization of hepatocellular carcinoma: prevalence and causative factors of extrahepatic collateral arteries in 479 patients. Korean J Radiol (2006) 1.07
Sticky nanoparticles: a platform for siRNA delivery by a bis(zinc(II) dipicolylamine)-functionalized, self-assembled nanoconjugate. Angew Chem Int Ed Engl (2011) 1.07
PEGylation of hyaluronic acid nanoparticles improves tumor targetability in vivo. Biomaterials (2010) 1.07
The hydrogel template method for fabrication of homogeneous nano/microparticles. J Control Release (2009) 1.07
Left subclavian artery stenosis in coronary artery bypass: prevalence and revascularization strategies. Ann Thorac Surg (2010) 1.06
Various findings of cardiac thrombi on MDCT and MRI. J Comput Assist Tomogr (2006) 1.06
Polymorphisms in TGF-beta1 gene and the risk of lung cancer. Lung Cancer (2006) 1.05
Local drug delivery via a coronary stent with programmable release pharmacokinetics. Circulation (2003) 1.04
Tumor-homing poly-siRNA/glycol chitosan self-cross-linked nanoparticles for systemic siRNA delivery in cancer treatment. Angew Chem Int Ed Engl (2012) 1.04
Safety and convenience of continuous warfarin strategy during the periprocedural period in patients who underwent catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol (2009) 1.03
Hydrophobically modified glycol chitosan nanoparticles as carriers for paclitaxel. J Control Release (2006) 1.03
Development of an in vitro 3D tumor model to study therapeutic efficiency of an anticancer drug. Mol Pharm (2013) 1.01
Hydrotropic solubilization of poorly water-soluble drugs. J Pharm Sci (2010) 1.01
Real-time and non-invasive optical imaging of tumor-targeting glycol chitosan nanoparticles in various tumor models. Biomaterials (2011) 1.00
Tumor-targeting hyaluronic acid nanoparticles for photodynamic imaging and therapy. Biomaterials (2012) 1.00
Stability and cellular uptake of polymerized siRNA (poly-siRNA)/polyethylenimine (PEI) complexes for efficient gene silencing. J Control Release (2009) 1.00
In situ visualization of paclitaxel distribution and release by coherent anti-Stokes Raman scattering microscopy. Anal Chem (2006) 1.00
Retrospective versus prospective ECG-gated dual-source CT in pediatric patients with congenital heart diseases: comparison of image quality and radiation dose. Int J Cardiovasc Imaging (2010) 1.00
Collateral pathways in thoracic central venous obstruction: three-dimensional display using direct spiral computed tomography venography. J Comput Assist Tomogr (2004) 0.99
Effects of nitroglycerin on the diagnostic accuracy of electrocardiogram-gated coronary computed tomography angiography. J Comput Assist Tomogr (2008) 0.99
The role of perfusion CT as a follow-up modality after transcatheter arterial chemoembolization: an experimental study in a rabbit model. Invest Radiol (2010) 0.98
Effects of ethylene glycol-based graft, star-shaped, and dendritic polymers on solubilization and controlled release of paclitaxel. J Control Release (2003) 0.98
Percutaneous transsplenic access to the portal vein for management of vascular complication in patients with chronic liver disease. Cardiovasc Intervent Radiol (2011) 0.97
Hydrotropic polymer micelles as versatile vehicles for delivery of poorly water-soluble drugs. J Control Release (2011) 0.97
Hydrotropic polymer micelles containing acrylic acid moieties for oral delivery of paclitaxel. J Control Release (2008) 0.97
Hydrotropic dendrimers of generations 4 and 5: synthesis, characterization, and hydrotropic solubilization of paclitaxel. Bioconjug Chem (2004) 0.97
Extrahepatic collateral artery supply to the tumor thrombi of hepatocellular carcinoma invading inferior vena cava: the prevalence and determinant factors. J Vasc Interv Radiol (2008) 0.97
Experimental study on acute ischemic small bowel changes induced by superselective embolization of superior mesenteric artery branches with N-butyl cyanoacrylate. J Vasc Interv Radiol (2008) 0.97
Clinical significance of complete conduction block of the left lateral isthmus and its relationship with anatomical variation of the vein of Marshall in patients with nonparoxysmal atrial fibrillation. J Cardiovasc Electrophysiol (2009) 0.96
In vitro and in vivo test of PEG/PCL-based hydrogel scaffold for cell delivery application. J Control Release (2007) 0.96
Long duration of radiofrequency energy delivery is an independent predictor of clinical recurrence after catheter ablation of atrial fibrillation: over 500 cases experience. Int J Cardiol (2012) 0.96
Enhanced drug-loading and therapeutic efficacy of hydrotropic oligomer-conjugated glycol chitosan nanoparticles for tumor-targeted paclitaxel delivery. J Control Release (2013) 0.95
Transcatheter arterial chemoembolization with paclitaxel-lipiodol solution in rabbit VX2 liver tumor. Radiology (2003) 0.95
Hypertrophic cardiomyopathy: assessment with MR imaging and multidetector CT. Radiographics (2010) 0.95